Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Polycystic Ovary Syndrome (PCOS) Drugs Market 2021-2025

Published by TechNavio (Infiniti Research Ltd.) Product code 990076
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Polycystic Ovary Syndrome (PCOS) Drugs Market 2021-2025
Published: February 15, 2021 Content info: 120 Pages
Description

Technavio has been monitoring the polycystic ovary syndrome (PCOS) drugs market and it is poised to grow by $ 711.14 mn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on polycystic ovary syndrome (PCOS) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases and growth in the geriatric women population. In addition, increasing prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The polycystic ovary syndrome (PCOS) drugs market analysis includes application segment and geographical landscapes.

Technavio's polycystic ovary syndrome (PCOS) drugs market is segmented as below:

By Application

  • Insulin sensitizing agents
  • Oral contraceptives
  • Aromatase inhibitors
  • Other drug classes

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies increasing rate of unplanned pregnancies and unnecessary abortions as one of the prime reasons driving the polycystic ovary syndrome (PCOS) drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on polycystic ovary syndrome (PCOS) drugs market covers the following areas:

  • Polycystic ovary syndrome (PCOS) drugs market sizing
  • Polycystic ovary syndrome (PCOS) drugs market forecast
  • Polycystic ovary syndrome (PCOS) drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading polycystic ovary syndrome (PCOS) drugs market vendors that include AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the polycystic ovary syndrome (PCOS) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR70204

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Drug Class

  • Market segments
  • Comparison by drug class
  • Insulin sensitizing agents - Market size and forecast 2020-2025
  • Oral contraceptives - Market size and forecast 2020-2025
  • Aromatase inhibitors - Market size and forecast 2020-2025
  • Other drug classes - Market size and forecast 2020-2025
  • Market opportunity by drug class

Customer landscape

  • Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Competitive scenario
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • Ferring Pharmaceuticals AS
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Other1 - Market share 2020-2025 (%)
  • 22: Comparison by Other1
  • 23: Insulin sensitizing agents - Market size and forecast 2020-2025 ($ million)
  • 24: Insulin sensitizing agents - Year-over-year growth 2020-2025 (%)
  • 25: Oral contraceptives - Market size and forecast 2020-2025 ($ million)
  • 26: Oral contraceptives - Year-over-year growth 2020-2025 (%)
  • 27: Aromatase inhibitors - Market size and forecast 2020-2025 ($ million)
  • 28: Aromatase inhibitors - Year-over-year growth 2020-2025 (%)
  • 29: Other drug classes - Market size and forecast 2020-2025 ($ million)
  • 30: Other drug classes - Year-over-year growth 2020-2025 (%)
  • 31: Market opportunity by Other1
  • 32: Customer landscape
  • 33: Market share by geography 2020-2025 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2020-2025 ($ million)
  • 36: North America - Year-over-year growth 2020-2025 (%)
  • 37: Europe - Market size and forecast 2020-2025 ($ million)
  • 38: Europe - Year-over-year growth 2020-2025 (%)
  • 39: Asia - Market size and forecast 2020-2025 ($ million)
  • 40: Asia - Year-over-year growth 2020-2025 (%)
  • 41: ROW - Market size and forecast 2020-2025 ($ million)
  • 42: ROW - Year-over-year growth 2020-2025 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: AbbVie Inc. - Overview
  • 52: AbbVie Inc. - Business segments
  • 53: AbbVie Inc. - Key offerings
  • 54: AbbVie Inc. - Key customers
  • 55: AbbVie Inc. - Segment focus
  • 56: Bayer AG - Overview
  • 57: Bayer AG - Business segments
  • 58: Bayer AG - Key offerings
  • 59: Bayer AG - Key customers
  • 60: Bayer AG - Segment focus
  • 61: Bristol-Myers Squibb Co. - Overview
  • 62: Bristol-Myers Squibb Co. - Product and service
  • 63: Bristol-Myers Squibb Co. - Key offerings
  • 64: Bristol-Myers Squibb Co. - Key customers
  • 65: Bristol-Myers Squibb Co. - Segment focus
  • 66: Cipla Inc. - Overview
  • 67: Cipla Inc. - Business segments
  • 68: Cipla Inc. - Key offerings
  • 69: Cipla Inc. - Key customers
  • 70: Cipla Inc. - Segment focus
  • 71: Ferring Pharmaceuticals AS - Overview
  • 72: Ferring Pharmaceuticals AS - Product and service
  • 73: Ferring Pharmaceuticals AS - Key offerings
  • 74: Ferring Pharmaceuticals AS - Key customers
  • 75: Ferring Pharmaceuticals AS - Segment focus
  • 76: Merck & Co. Inc. - Overview
  • 77: Merck & Co. Inc. - Business segments
  • 78: Merck & Co. Inc. - Key offerings
  • 79: Merck & Co. Inc. - Key customers
  • 80: Merck & Co. Inc. - Segment focus
  • 81: Novartis AG - Overview
  • 82: Novartis AG - Business segments
  • 83: Novartis AG - Key offerings
  • 84: Novartis AG - Key customers
  • 85: Novartis AG - Segment focus
  • 86: Pfizer Inc. - Overview
  • 87: Pfizer Inc. - Business segments
  • 88: Pfizer Inc. - Key offerings
  • 89: Pfizer Inc. - Key customers
  • 90: Pfizer Inc. - Segment focus
  • 91: Sun Pharmaceutical Industries Ltd. - Overview
  • 92: Sun Pharmaceutical Industries Ltd. - Business segments
  • 93: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 94: Sun Pharmaceutical Industries Ltd. - Key customers
  • 95: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 96: Teva Pharmaceutical Industries Ltd. - Overview
  • 97: Teva Pharmaceutical Industries Ltd. - Business segments
  • 98: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 99: Teva Pharmaceutical Industries Ltd. - Key customers
  • 100: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations
Back to Top